Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment
The vaccine further advances Pfizer’s vaccine portfolio and builds on more than 20 years of expertise and knowledge in the prevention of meningococcal disease
ASMD is highly variable and the age of onset, specific symptoms and severity of the disorder can vary dramatically from one person to another
Pant delivers keynote address at National Conclave on “Augmented Zoonotic Diseases Surveillance at Human – Wildlife Interface”
Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year
In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers
Jeet will be a trusted partner in cardiovascular care
The partnership aims to prioritize the diagnosis and treatment of these diseases while working to reducing their long-term prevalence
Health Secretary highlights the need for capacity building programmes for Medical Officers to tackle Non Communicable Diseases at the primary level
These initiatives aim to improve access to healthcare for rare disease patients
Subscribe To Our Newsletter & Stay Updated
